CX Institutional
ALNY icon

CX Institutional’s Alnylam Pharmaceuticals ALNY Stock Holding History

CX Institutional’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$19K Buy
+76
New +$19.3K ﹤0.01% 1239
2026
Q2 		– Sell
-4
Closed -$1K – 1573
2026
Q1 		$1K Sell
4
-1
-20% -$340 ﹤0.01% 1479
2025
Q4 		$2K Buy
+5
New +$2.21K ﹤0.01% 1346

Other funds holding ALNY

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
MN Services Vermogensbeheer
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
IFM Investors
IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return
Portman Square Capital
Portman Square Capital London, United Kingdom $1.77B AUM 15.29% 1-Year Est. Return
Fideuram - Intesa Sanpaolo Private Banking
Fideuram - Intesa Sanpaolo Private Banking Turin $3.5B AUM 45.13% 1-Year Est. Return
PensionDanmark
PensionDanmark Copenhagen O, Denmark $12.3B AUM 33.99% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Sumitomo Mitsui DS Asset Management
Sumitomo Mitsui DS Asset Management Tokyo, Japan $14.8B AUM 30.39% 1-Year Est. Return

CX Institutional's ALNY Position: Q3 2026 in Review

CX Institutional opened a new position in Alnylam Pharmaceuticals (ALNY) in Q3 2026: 76 shares worth $19K. The stake represents ﹤0.01% of the portfolio and ranks #1239 among its holdings. This is a return to the name: CX Institutional previously reported a position in ALNY as recently as Q1 2026.

CX Institutional first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. 128 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • CX Institutional held 76 shares of Alnylam Pharmaceuticals worth $19K as of Q3 2026.
  • Alnylam Pharmaceuticals was a new CX Institutional position in Q3 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of CX Institutional's portfolio in Q3 2026, its #1239 holding.
  • CX Institutional first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 128 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on CX Institutional's 13F filing for Q3 2026, filed 2 Oct 2026.